Last reviewed: June 12, 2026
Last updated: June 12, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has become one of the most discussed weight-loss medications in recent years, with clinical trials demonstrating an average weight loss of 15 to 22 percent of baseline body weight when used consistently. Understanding realistic outcomes and how your individual genetics influence your response can help you make informed decisions about whether semaglutide is right for your health journey. PlexusDx provides access to compounded semaglutide injections tailored to your unique peptide-pathway genetics, offering transparent pricing and no flat per-compound pricing changes.
Average Semaglutide Weight Loss Results from Clinical Trials
The landmark STEP trials (Semaglutide Treatment Effect in People with obesity) enrolled over 4,500 adults and measured weight loss across 68 weeks of treatment. Participants receiving the 2.4 mg weekly maintenance dose lost an average of 14.9 kg (approximately 15% of their starting weight), compared to just 2.6 kg in the placebo group. In the highest-dose cohort, some participants achieved weight reductions exceeding 22% of their baseline body weight, though individual results varied considerably based on metabolism, adherence, and lifestyle factors.
Real-world data from clinical practices shows similar patterns, with most semaglutide users reporting meaningful weight loss within the first 8 to 12 weeks of treatment. The medication works by slowing stomach emptying and signaling fullness to your brain, creating a sustained reduction in appetite that translates to lower calorie intake without constant willpower battles. Most people experience the most significant weight loss during months 2 through 6, with a plateau phase typically occurring by month 12, though maintenance of lost weight continues as long as treatment continues.
Why Individual Weight Loss Varies on Semaglutide
Not everyone loses the same amount of weight on semaglutide, even at identical doses, because weight loss depends on your genetic predisposition to respond to GLP-1 receptor signaling. Your FTO gene variant (rs9939609) influences how your body regulates appetite and energy expenditure, while your GLP1R variant (rs6923761) determines how effectively semaglutide activates the receptors that trigger fullness signals. Additional factors including your baseline metabolic rate, insulin sensitivity, existing medical conditions, dietary habits, and physical activity level all modulate the degree of weight loss you'll experience.
PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and analyzes 49 peptides to identify your specific genetic profile across weight-regulation genes including GIPR (rs1800437) and MC4R (rs17782313). This personalized insight allows your PlexusDx provider to optimize your semaglutide dose and consider alternative or complementary therapies if your genetic pattern suggests a less robust response to GLP-1 alone, ensuring you get maximum results from your treatment plan.
Semaglutide Dose Escalation and Weight Loss Progression
Semaglutide therapy typically begins at a low introductory dose and increases gradually over 16 weeks to minimize nausea and gastrointestinal side effects while your body adapts to the medication. Most providers start with 0.25 mg weekly, then step up to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg maintenance dose. This slow escalation allows your system to acclimate, and many patients notice appetite suppression kicking in even at lower doses, with progressive weight loss acceleration as they move through the dose ladder.
PlexusDx's pricing model reinforces an important principle: your dose may need to go up as your body adapts, but your monthly cost stays flat at $149 starting price across all dose levels. This removes the financial barrier to dose optimization and ensures you can safely reach your therapeutic dose without worrying about escalating expenses. Some patients achieve meaningful results at 1.0 or 1.7 mg, while others need the full 2.4 mg maintenance dose—PlexusDx supports whatever progression your provider determines is best for your goals.
Comparing Semaglutide to Other GLP-1 Options at PlexusDx
Semaglutide injection (starting at $149/month) remains PlexusDx's most affordable GLP-1 option, but the company also offers tirzepatide, a dual GLP-1/GIP receptor agonist that some research suggests may produce greater weight loss than semaglutide alone. Tirzepatide injections start at $249/month, and oral forms of both medications are available for patients who prefer tablets over injections. PlexusDx also offers GLP-Squared (a dual-compound semaglutide-plus-tirzepatide injection starting at $249/month) for patients whose genetics or trial experience suggests synergistic benefit from combining both compounds.
Your choice between these options should factor in your Precision Peptide genetic test results, your preference for injection versus oral administration, your tolerance for side effects, and your weight-loss goals. PlexusDx's providers use your genetic insights to recommend the medication most likely to work for your specific metabolic wiring, maximizing your chance of achieving significant, sustainable weight loss without unnecessary trial-and-error switching.
Realistic Timeline for Semaglutide Weight Loss Results
Most semaglutide users notice the first signs of appetite suppression within days to a few weeks of starting the medication, though visible weight loss typically appears 3 to 4 weeks into treatment. By week 8 to 12, most people report losing 5 to 10 pounds, and the pace often accelerates through months 3 and 4 as the dose continues climbing and your body fully adjusts to the medication. Peak weight loss generally occurs around month 5 to 6, after which the rate of loss typically slows, though many people continue losing 1 to 2 pounds per week even in the plateau phase if they maintain their lifestyle habits.
PlexusDx recommends tracking your progress with regular weigh-ins and body measurements, as the scale doesn't capture muscle gain from increased physical activity or body composition improvements that happen simultaneously with fat loss. Most patients experience non-scale victories like improved energy, better sleep, reduced cravings, clearer thinking, and improved blood sugar control even before reaching their ultimate weight-loss goal, making the journey rewarding beyond the numbers on the scale.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How much weight will I lose on semaglutide?
Clinical trials show average weight loss of 15–22% of baseline body weight over 68 weeks, but individual results depend on your genetics, starting weight, diet, and exercise. PlexusDx's Precision Peptide Genetic Test identifies your specific GLP1R and FTO variants to predict your likely response and optimize your dose for maximum results.
How quickly do people see weight loss on semaglutide?
Most users feel appetite suppression within days to weeks, with visible weight loss typically appearing 3–4 weeks into treatment. Peak weight loss momentum usually occurs around months 5–6 as your dose reaches maintenance levels and your body fully adapts.
Is semaglutide injection from PlexusDx real medication?
Yes, PlexusDx sources all semaglutide from licensed 503A compounding pharmacies and serves all 50 states without requiring insurance. Your compounded medication is prepared to pharmaceutical standards and tailored to your personalized dosing plan starting at $149/month.
What if semaglutide doesn't work for my weight loss?
If your genetic profile or early trial results suggest a weaker GLP-1 response, PlexusDx providers may recommend tirzepatide (a GLP-1/GIP dual agonist), oral semaglutide, or GLP-Squared (a dual-compound injection combining both). Your Precision Peptide Genetic Test guides these decisions to avoid wasting time on suboptimal therapies.
Does PlexusDx offer genetic testing to predict my semaglutide results?
Yes, the Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 14 metabolic pathways and 150+ genetic insights including your GLP1R, GIPR, FTO, and MC4R variants. This personalized data helps your provider optimize your semaglutide dose and predict your likely weight-loss trajectory based on your biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What is a Therapeutic Dose of Tirzepatide for Effective Weight Management?
How Quickly Does Tirzepatide Curb Your Appetite? Navigating Your Weight Loss Journey